TRACK BRANDS ON AI
Monitor your brand, company, or product's online reputation in AI responses
Searching...
Loading...
It's taking longer than usual, we might be experiencing higher load.
Give it a few more seconds or try again in a moment.
Give it a few more seconds or try again in a moment.
Searching...
Loading...
What does AI know about Sarepta Therapeutics Inc ?
What does OpenAI free version (gpt-3.5-turbo) know about Sarepta Therapeutics Inc?
| Last request | 19.11.2023 |
| Well Known | Yes |
| Description | Sarepta Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. |
| Most Notable Achievements | Sarepta Therapeutics Inc. has developed a number of treatments for rare neuromuscular diseases, including Exondys 51, the first approved treatment for Duchenne muscular dystrophy. |
| The Most Negative Fact | Sarepta Therapeutics Inc. has faced criticism for the high cost of its treatments. |
| Competition | None |
| Share with friends |
Register your email below to unlock features!
Don't like the AI answers? Who can help me Change them?
What does OpenAI paid version (gpt-4) know about Sarepta Therapeutics Inc?
| Request date | |
| Well Known | Yes |
| Description | Sarepta Therapeutics Inc is a biopharmaceutical company that focuses on developing RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. |
| Most Notable Achievements | Sarepta Therapeutics Inc has developed a drug called Exondys 51, which is the first FDA-approved treatment for Duchenne muscular dystrophy. |
| The Most Negative Fact | Sarepta Therapeutics Inc has faced controversy and criticism over the high cost of their drugs. |
| Competition | None |
| Share with friends |
What does Google AI (PaLM) know about Sarepta Therapeutics Inc?
| Last request | 17.12.2023 |
| Well Known | yes |
| Description | Sarepta Therapeutics, Inc. is a biopharmaceutical company that develops RNA-based therapeutics for the treatment of rare neuromuscular diseases. |
| Most Notable Achievements | The company's lead product candidate, Exondys 51, is a small interfering RNA (siRNA) that targets the dystrophin gene and is currently in Phase III clinical trials for the treatment of Duchenne muscular dystrophy. |
| The Most Negative Fact | The company has been criticized for its high price tag for Exondys 51, which is estimated to cost $300,000 per year. |
| Competition | None |
What does Microsoft Bing AI know about Sarepta Therapeutics Inc?
| Well Known | Yes |
| Description | rteceepsosvosssatnont ra ntaprae rtic dioohpi nigrehptoc e dncl.senemuapucotus ociyucyadlcSm v fslb s deaoef recd ao aiiaeattnu iicre dnTusie mrpera e iaeImheemcn .e r |
| Most Notable Achievements | ueea caunelpx uSreemsd aytfluntcerndEtry m h eto teIatmuidvrb emf 1 Th nr.nansamyelo,hote sso c5st unugpidphris urDepter odi eaaecorssfedeeoit.cnrrsnapae snpa r,asoutrflvrdchr |
| The Most Negative Fact | Ttussht.Simnmec roh iaof ir ehIeeht.ttsiicaf a scorhacef et ttscrpstng cadp irae |
| Competition | Noen |
Register your email below to unlock features!
Looks like you haven't registered an account yet?
Just search for a brand, person or top-list BELOW and register your email on the search results page:
